博济医药
(300404)
| 流通市值：18.34亿 | | | 总市值：25.44亿 |
| 流通股本：2.75亿 | | | 总股本：3.82亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 358,782,705.15 | 232,360,196.3 | 103,299,782.23 | 423,682,626.42 |
| 营业收入 | 358,782,705.15 | 232,360,196.3 | 103,299,782.23 | 423,682,626.42 |
| 二、营业总成本 | 346,366,338.45 | 222,341,694.12 | 95,145,102.03 | 398,468,454.86 |
| 营业成本 | 229,452,106.46 | 147,785,155.44 | 62,805,195.55 | 262,970,225.46 |
| 税金及附加 | 3,377,974.68 | 2,144,112.3 | 1,013,159.37 | 4,032,274.7 |
| 销售费用 | 30,824,217.84 | 18,108,784.75 | 7,095,599.83 | 31,095,979.46 |
| 管理费用 | 46,693,280.48 | 31,409,035.96 | 14,539,602.98 | 57,556,037.38 |
| 研发费用 | 36,540,647.19 | 23,456,248.79 | 9,986,450.82 | 43,676,568.67 |
| 财务费用 | -521,888.2 | -561,643.12 | -294,906.52 | -862,630.81 |
| 其中:利息费用 | 1,094,453.36 | 637,400.59 | 244,995.48 | 704,292.22 |
| 其中:利息收入 | 1,748,502.6 | 1,297,037.42 | 606,825.47 | 1,677,772.86 |
| 加:公允价值变动收益 | 542,155.83 | 205,462.88 | 149,609.28 | 1,791,081.57 |
| 加:投资收益 | 990,335.62 | 605,510.53 | 125,710.2 | 1,962,445.02 |
| 资产处置收益 | 931.96 | - | - | - |
| 资产减值损失(新) | -2,358,936.41 | -1,275,317.16 | 10,218.68 | -10,522,115.38 |
| 信用减值损失(新) | -5,988,508.81 | -4,431,836.87 | -1,973,757.33 | -9,309,530.87 |
| 其他收益 | 11,419,778.17 | 9,934,099.48 | 6,365,552.97 | 10,399,940.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 17,022,123.06 | 15,056,421.04 | 12,832,014 | 19,535,991.98 |
| 加:营业外收入 | 138,677.54 | 20,097.28 | 20,094.9 | 5,178,919.76 |
| 减:营业外支出 | 34,127.57 | 13,925.15 | 13,860.84 | 142,626.01 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 17,126,673.03 | 15,062,593.17 | 12,838,248.06 | 24,572,285.73 |
| 减:所得税费用 | -7,720,506.28 | -3,595,199.03 | 493,436.51 | -4,740,145.65 |
| 六、净利润 | 24,847,179.31 | 18,657,792.2 | 12,344,811.55 | 29,312,431.38 |
| 持续经营净利润 | 24,847,179.31 | 18,657,792.2 | 12,344,811.55 | 29,312,431.38 |
| 归属于母公司股东的净利润 | 23,022,627.61 | 17,619,050.53 | 11,738,526.83 | 27,669,540.69 |
| 少数股东损益 | 1,824,551.7 | 1,038,741.67 | 606,284.72 | 1,642,890.69 |
| (一)基本每股收益 | 0.06 | 0.05 | 0.03 | 0.08 |
| (二)稀释每股收益 | 0.06 | 0.05 | 0.03 | 0.08 |
| 八、其他综合收益 | 1,123,469.02 | 1,641,713.38 | -534,887.84 | 3,409,966.46 |
| 归属于母公司股东的其他综合收益 | 1,067,295.57 | 1,559,627.71 | -508,143.45 | 3,239,468.14 |
| 九、综合收益总额 | 25,970,648.33 | 20,299,505.58 | 11,809,923.71 | 32,722,397.84 |
| 归属于母公司股东的综合收益总额 | 24,089,923.18 | 19,178,678.24 | 11,230,383.38 | 30,909,008.83 |
| 归属于少数股东的综合收益总额 | 1,880,725.15 | 1,120,827.34 | 579,540.33 | 1,813,389.01 |
| 公告日期 | 2023-10-27 | 2023-08-26 | 2023-04-26 | 2023-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |